Prostate cancer represents one of the most prevalent malignancies in the world. Although subsets of prostate cancer are aggressive and can metastasize, it is also evident that most patients harbor indolent disease. Although current risk-stratification approaches use both clinical and pathologic factors, it is clear that biomarkers can be used to improve on these approaches. In this article, we review the currently published literature on prostate cancer molecular biomarkers, primarily in the context of radiation therapy, focusing on those found in serum, plasma, urine, and within the tumor biopsy itself. We highlight the potential use and limitations of these biomarkers and present possible future directions for biomarker investigation.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Seminars in radiation oncology. 2016 Sep 16 [Epub]
William A Hall, Colleen A Lawton, Ashesh B Jani, Alan Pollack, Felix Y Feng
Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI., Department of Radiation Oncology, Emory University, Atlanta, GA., Department of Radiation Oncology, University of Miami, Coral Gables, FL., Departments of Radiation Oncology, Urology, and Medicine, University of California San Francisco, San Francisco, CA. Electronic address: .